Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
Review

On the horizon: Extracorporeal carbon dioxide removal

Justin Hanks, DO, Steven Fox, MD, Omar Mehkri, MD, Laura W. Lund, PhD, Tracey Dill, RRT, Abhijit Duggal, MD, MPH, MSc and Sudhir Krishnan, MD
Cleveland Clinic Journal of Medicine December 2022, 89 (12) 712-718; DOI: https://doi.org/10.3949/ccjm.89a.21084
Justin Hanks
Pulmonary and Critical Care Fellowship, Respiratory Institute, Cleveland Clinic, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: [email protected]
Steven Fox
Assistant Professor, Division of Pulmonary, Allergy, and Critical Care, University of Alabama, Birmingham, AL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Omar Mehkri
Department of Critical Care Medicine, Respiratory Institute, Cleveland Clinic, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura W. Lund
Consultant at Lund MDC, Pittsburgh, PA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tracey Dill
Vice-President of Clinical Operations, ALung Technologies Inc., Pittsburgh, PA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Abhijit Duggal
Department of Critical Care Medicine, Respiratory Institute, Cleveland Clinic, Cleveland, OH; Associate Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Find this author on Cleveland Clinic
Sudhir Krishnan
Department of Critical Care Medicine, Respiratory Institute, Cleveland Clinic, Cleveland, OH; Assistant Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Find this author on Cleveland Clinic
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Extracorporeal carbon dioxide removal (ECCO2R) uses mechanical systems to treat hypercapnic respiratory failure. Its utility has been investigated in acute respiratory distress syndrome (ARDS), acute exacerbations of chronic obstructive pulmonary disease (COPD), and status asthmaticus, and as a bridge to lung transplant. In this review, we discuss how it works, why it should help, and current evidence supporting its use.

KEY POINTS
  • While ECCO2R may help facilitate low tidal volume ventilation in ARDS, evidence that it improves the survival rate is as yet wanting.

  • Similarly, although this therapy appears promising in other indications, evidence is still sparse.

  • The risks associated with ECCO2R, including hemorrhage, must be weighed against its purported clinical benefits.

  • At this time, the use of ECCO2R, promising as it is, should be explored within the confines of clinical research with a view to improving its safety and efficacy.

Extracorporeal carbon dioxide removal (ECCO2R) is similar to extracorporeal membrane oxygenation (ECMO) in that it involves shunting blood through a membrane device. But unlike ECMO, it does not provide significant oxygenation. The primary purpose is to remove carbon dioxide. Compared with ECMO, ECCO2R can be used with lower blood flow rates and smaller cannulas.1 It may also be less expensive and easier to implement.

ECCO2R has been studied in various pulmonary diseases, eg, acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD),2 and asthma,3 and as a bridge to lung transplant.4 Currently, only one ECCO2R device is approved by the US Food and Drug Administration, for use of up to 5 days.

As use of ECCO2R becomes more widespread, physicians will need to get more familiar with it. Extracorporeal life support technologies such as ECMO and ECCO2R require highly specialized training and technology.5 The Extracorporeal Life Support Organization currently lists 351 ECMO-certified centers in the United States.6

This article, a primer for clinicians, provides an overview of ECCO2R including the rationale for its use, how it works, and evidence of its benefits.

WHY REMOVE CARBON DIOXIDE?

Hypercapnia and ensuing acidosis have detrimental effects on multiple body systems. Hypercapnia decreases myocardial contractility and increases pulmonary vasoconstriction, which could worsen right ventricular afterload, perpetuating right ventricular failure.7 Hypercapnic acidemia may also contribute to lung injury by increasing production of nitric oxide. But on the other hand, it mitigates lung injury by decreasing reactive oxygen species, ie, superoxides. Theoretical benefits of ECCO2R include the following:

Avoiding barotrauma. Normally, we get rid of carbon dioxide by breathing it out, and for a patient on a ventilator, to get rid of more carbon dioxide, we would have to turn up the tidal volume, the ventilation rate, or both. But increasing the tidal volume can cause barotrauma. ECCO2R allows us to keep the tidal volume low.

Slightly better oxygenation. As the arterial partial pressure of carbon dioxide goes down, the partial pressure of oxygen in the alveoli should go up according to the alveolar gas equation—whereby, basically, the alveolar partial pressure of oxygen equals the fraction of inspired oxygen minus the partial pressure of carbon dioxide. Also, ECCO2R, by correcting hypercapnia, allows the ventilation strategy to focus on oxygenation.8

CARBON DIOXIDE PHYSIOLOGY

Carbon dioxide is the product of metabolism within mitochondria.9 With the help of the enzyme carbonic anhydrase, mostly in red blood cells, it combines with water to form carbonic acid, which dissociates into bicarbonate and hydrogen ions. All of these reactions are reversible, and although there is far more bicarbonate than dissolved carbon dioxide circulating in the blood, bicarbonate can rapidly be converted back to carbon dioxide as the latter is removed from the blood through breathing, maintaining the partial pressure of carbon dioxide.

Carbon dioxide is transported in the blood both dissolved in plasma and bound to hemoglobin, but the blood’s carrying capacity for carbon dioxide is not limited by the hemoglobin concentration and binding capacity, as it is for oxygen. Compared with oxygen, carbon dioxide is more soluble and diffusible in the blood and has a linear hemoglobin dissociation curve that keeps going up, whereas that of oxygen reaches a plateau.

Given these differences in transport and dissociation physiology, carbon dioxide removal is more effective than oxygen delivery at lower blood-flows.

ECCO2R SYSTEMS

The typical ECCO2R setup (Figure 1) has 3 essential parts: the catheter or catheters, the membrane “lung,” and a pump (depending on the system) to circulate the blood.1 Because the equipment continues to evolve and get more complicated, the Extracorporeal Life Support Organization10 has developed standardized nomenclature to describe ECCO2R systems based on catheter function (drainage, reinfusion, or both), access site, size, and tip placement.

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1

Basic venovenous extracorporeal carbon dioxide removal circuit.

ECCO2R systems are frequently classified as either venovenous or arteriovenous. Venovenous systems take blood from a vein and return it to a vein, sometimes the same vein. A pump generates the necessary flow, allowing cannulation through low-pressure venous vessels, often with a single, dual-lumen, bicaval catheter (Figure 1). Arteriovenous systems usually use 2 single-lumen cannulas, which take blood from an artery and return it to a vein, with the arterial pressure driving blood flow. Such pumpless systems, while causing less blood trauma, require adequate cardiac output and larger cannulas to maintain adequate blood flow.

ECCO2R systems typically operate at lower flow rates than ECMO systems, as low as 250 mL/minute in combined ECCO2R-hemodialysis systems.11

Table 1 compares key features of ECCO2R and ECMO systems.

View this table:
  • View inline
  • View popup
TABLE 1

Differences between extracorporeal carbon dioxide removal (ECCO2R) and extracorporeal membrane oxygenation (ECMO)

CARBON DIOXIDE REMOVAL MECHANISMS

ECCO2R systems use 2 main methods to remove carbon dioxide from blood.12

The membrane lung technique, the more common method, directly removes dissolved carbon dioxide by diffusion. Blood is circulated through microscopic channels on one side of a membrane, while gas without any carbon dioxide in it (the “sweep” gas) flows on the other side, generating a gradient so that the carbon dioxide diffuses across out of blood into this column of moving air. Other factors affecting carbon dioxide removal include the oxygen concentration in the sweep gas, the surface area of the membrane, and the rate of blood flow.

The respiratory dialysis technique removes carbon dioxide indirectly by removing bicarbonate ions by hemodialysis. By itself, this would make acidemia worse because it leaves the acidic hydrogen ions in place while removing the basic bicarbonate ions.13 To counter this deleterious effect, hydroxide and tris(hydroxy-methyl)aminomethane need to be infused, which can lead to hemolysis and arrhythmias. However, a 2020 study in pigs demonstrated the feasibility of this method by using a low-bicarbonate dialysate and avoiding blood acidification.14

Bicarbonate removal through ultrafiltration rather than hemodialysis has also been studied and can perform at lower blood flow rates than hemodialysis.15

ACUTE RESPIRATORY DISTRESS SYNDROME

About 10% of patients in intensive care units and 20% to 25% of patients on mechanical ventilators are there because they have ARDS.16 It is a heterogeneous syndrome caused by a dysregulated inflammatory response resulting in damage to the interface between the capillary endothelium and alveolar epithelium. This in turn leads to increased capillary permeability, noncardiogenic pulmonary edema, and decreased lung compliance.

A low-tidal-volume strategy is the cornerstone of ARDS management. Setting the ventilator to a lower tidal volume improves survival outcomes by reducing ventilator-induced lung injury, but it also leads to hypercapnia due to decreased alveolar ventilation. ECCO2R has undergone trials to see if it can alleviate this effect and permit low-tidal-volume ventilation (4–6 mL/kg predicted body weight) or even ultralow-tidal-volume ventilation (< 4 mL/kg predicted body weight).

While interest in using ECCO2R in ARDS dates back to the 1980s, investigation is ongoing.

The Xtravent study (Extrapulmonary Interventional Ventilatory Support in Severe Acute Respiratory Distress Syndrome),17 in 2013, compared ultralow-tidal-volume ventilation (about 3 mL/kg) plus ECCO2R vs about 6 mL/kg without ECCO2R in 79 patients with ARDS. Neither the number of ventilation-free days nor the mortality rate differed between the 2 treatment groups.

The SUPERNOVA trial (Strategy of Ultra-Protective Lung Ventilation with Extracorporeal CO2 Removal for new-Onset Moderate to Severe ARDS),18 in 2019, tested the feasibility of ECCO2R in maintaining ultralow tidal volume (4 mL/kg) in 95 patients with ARDS, 33 of whom were treated with a lower-powered carbon dioxide extraction machine and 62 with a higher-powered machine. Combining both groups, ultralow-tidal-volume ventilation was obtained by 24 hours in 82% of patients (64% with the low-powered machines and 92% with the high-powered machines, P < .001), with tidal volume, respiratory rate, minute ventilation, plateau pressure, and driving pressure significantly lower than at baseline; 69 patients (62%) survived to hospital discharge.19

The REST trial (Protective Ventilation With Veno-venous Lung Assist in Respiratory Failure),20 in 2021, found no statistically significant reduction in mortality at 90 days. A concern with this trial is that patients were recruited based on severity of hypoxemia rather than ARDS criteria, which only 60% met at enrollment. A significant number of patients may not have exhibited conventional ARDS physiologic patterns, such as increased alveolar dead-space fraction and decreased respiratory system compliance. Studies have shown that these 2 factors, rather than severity of hypoxemia, may be better entry criteria in ECCO2R studies.21 Also, the trial was stopped early due to futility and thus may have lacked power to detect a clinically important difference in mortality.

Acute respiratory distress syndrome due to COVID-19

ARDS due to COVID-19 can progress to hypercapnic respiratory failure,22 and ECCO2R has been used in this situation as well.

Akkanti et al23 reported that respiratory acidemia improved in 29 patients with its use, with peak effect within 24 hours. However, only 11 patients (38%) survived to hospital discharge. This high mortality rate (62%) is comparable to that in COVID-19 patients on ECMO (37% to 59%, worsening over time).24

Allescher et al25 studied the use of the Advanced Organ Support system (ADVOS), a combined ECCO2R-renal replacement-liver support system, in COVID-19 patients with mild to moderate ARDS. Multiple laboratory values improved (creatinine, blood urea nitrogen, pH, bicarbonate), but the in-hospital mortality rate was still 55%.

ACUTE EXACERBATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE

COPD is defined by chronic inflammation of the airways, pulmonary parenchyma, and vasculature.26 Its natural course includes episodes of acute deterioration (exacerbations), with a reported intensive care unit mortality rate of 25% in patients needing mechanical ventilation in 1 large study.27 ECCO2R has been investigated in this population to see if it can help patients avoid needing mechanical ventilation.

Kluge et al,28 in a retrospective study, reported that 19 of 21 patients for whom noninvasive ventilation had failed were able to avoid intubation by receiving ECCO2R.

Burki et al,29 in a pilot study in 20 patients in 2013, found that a venovenous device provided clinically useful levels of carbon dioxide removal, significantly lowering the partial pressure of arterial carbon dioxide and raising the pH.

Del Sorbo et al30 found a lower risk for intubation when bilevel positive airway pressure and ECCO2R were used together instead of bilevel positive airway pressure alone. In addition, the hospital mortality rate was lower in the ECCO2R group.

The ECLAIR study31 (Extracorporeal Lung Assist to Avoid Intubation in Patients Failing NIV for Hypercapnic ARF) found that 14 of 25 patients with acute COPD exacerbation for whom noninvasive ventilation failed were able to avoid intubation with ECCO2R.

Azzi et al,32 in a 2021 study, similarly examined ECCO2R use in patients who were at risk of noninvasive ventilation failure; 85% of the patients (22 of 26) avoided intubation. Complications in this study included major bleeding in 7 (20%) of the ECCO2R recipients, which was, however, less than in earlier studies,31 despite a higher body mass index than in the control group (30 vs 25 kg/m2).

STATUS ASTHMATICUS

Asthma is a chronic inflammatory disorder of the airways, defined by variable and at least partially reversible airflow obstruction due to bronchial hyperresponsiveness to a variety of triggers.33 As in COPD, the natural course is marked by exacerbations with episodes of acute respiratory distress caused by increases in airway swelling, secretions, and muscle constriction. The most extreme form is called status asthmaticus. These exacerbations are the reason for many intensive care unit admissions, with many patients requiring intubation (61% in 1 series).34,35

Tiruvoipati et al36 used ECCO2R to treat 15 patients with acute or acute-on-chronic respiratory failure of various etiologies, including 2 with acute asthma exacerbation that required mechanical ventilation. In these 2 patients, the partial pressure of arterial carbon dioxide returned to near-normal levels within 6 hours, and both were discharged alive from the hospital.

Bromberger et al37 applied ECCO2R in 26 intubated patients with status asthmaticus, whose arterial blood pH and arterial partial pressure of carbon dioxide improved, allowing for lowering of inflation pressures on the ventilator. Additionally, the use of vasopressors was significantly decreased after ECCO2R initiation. Twenty patients were extubated while on ECCO2R, and all survived to hospital discharge.

While more research is required to see if ECCO2R can lower the mortality rate in this population, extracorporeal life support in asthma patients is associated with higher survival rates than in patients with other indications for extracorporeal life support,38 and we hope this benefit may extend to ECCO2R. ECCO2R is not currently approved for this status asthmaticus.

A BRIDGE TO LUNG TRANSPLANT

Many patients with end-stage lung disease experience an acute decline in respiratory status while waiting for a transplant.39,40 This can necessitate a bridging strategy with ECMO or ECCO2R. In such patients, “awake” ECMO (ie, with the patient awake, on ECMO, not on a ventilator) has been shown to have more favorable outcomes compared with mechanical ventilation.41 Given that ECCO2R has smaller cannula sizes, easier insertion techniques, and lower flow rates than ECMO, it may be a better method for awake bridging42 in those with primary hypercapnic respiratory failure, including those waiting for a repeat lung transplant.43

Benazzo et al44 reported on 120 patients bridged with extracorporeal life support from 1998 to 2017, of whom 26 received ECCO2R.

Fischer et al40 reported on arteriovenous ECCO2R in 12 patients with end-stage lung disease of various causes with ventilation-refractory severe hypercapnia and respiratory acidosis awaiting lung transplant. Ten patients underwent transplant, despite positive blood cultures in 7, use of mechanical ventilation, and need for extracorporeal life support, all of which are contraindications to lung transplant in some centers.

COMPLICATIONS

ECCO2R has been associated with various complications. The complex interplay between the patient’s sera and the artificial materials used in any extracorporeal device can lead to systemic inflammation by activating coagulation factors, platelets, leukocytes, and complement.3

Hemorrhage is common and can be catheter-related or at other sites such as the stomach, lungs, or brain. Doyle and Hunt45 estimated an incidence of severe hemorrhage of nearly 40% in patients on ECMO, and the use of systemic anticoagulation alone does not seem to be associated with bleeding risk.

Hemolysis has been reported in 2% to 11%,3 with post hoc analysis of the SUPERNOVA data noting higher rates of hemolysis and bleeding in patients on low-flow than on high-flow systems.18

Limb ischemia can occur in 4% to 10% but is encountered more with arterial than with venous catheterization,12 and it is of less concern in single-site venous cannulations.

Thrombocytopenia has been reported in patients on ECCO2R in rates ranging from 2% to 13%.18,20

DISCLOSURES

Dr. Lund has disclosed consulting for ALung Technologies. Tracy Dill has disclosed employment with ALung Technologies. Dr. Duggal has disclosed work as advisor or review panel participant and principal or co-investigator of funded research for ALung Technologies. The other authors report no relevant financial relationships which, in the context of their contributions, could be perceived as a potential conflict of interest.

  • Copyright © 2022 The Cleveland Clinic Foundation. All Rights Reserved.

REFERENCES

  1. ↵
    1. Cove ME,
    2. MacLaren G,
    3. Federspiel WJ,
    4. Kellum JA
    . Bench to bedside review: extracorporeal carbon dioxide removal, past present and future. Crit Care 2012; 16(5):232. doi:10.1186/cc11356
    OpenUrlCrossRefPubMed
  2. ↵
    1. Ghazala L,
    2. Hanks J,
    3. Abhijit D,
    4. Hatipoglu U,
    5. Stoller JK
    . Acute respiratory failure due to acute exacerbation of chronic obstructive pulmonary disease: the spectrum of ventilator strategies. Clin Pulm Med 2019; 26(5):154–160. doi:10.1097/CPM.0000000000000331
    OpenUrlCrossRef
  3. ↵
    1. Staudinger T
    . Update on extracorporeal carbon dioxide removal: a comprehensive review on principles, indications, efficiency, and complications. Perfusion 2020; 35(6):492–508. doi:10.1177/0267659120906048
    OpenUrlCrossRefPubMed
  4. ↵
    1. Morelli A,
    2. Del Sorbo L,
    3. Pesenti A,
    4. Ranieri VM,
    5. Fan E
    . Extracorporeal carbon dioxide removal (ECCO2R) in patients with acute respiratory failure. Intensive Care Med 2017; 43(4):519–530. doi:10.1007/s00134-016-4673-0
    OpenUrlCrossRefPubMed
  5. ↵
    1. Oude Lansink-Hartgring A,
    2. van Minnen O,
    3. Vermeulen KM,
    4. van den Bergh WM; Dutch Extracorporeal Life Support Study Group
    . Hospital costs of extracorporeal membrane oxygenation in adults: a systematic review. Pharmacoecon Open 2021; 5(4):613–623. doi:10.1007/s41669-021-00272-9
    OpenUrlCrossRef
  6. ↵
    1. Extracorporeal Life Support Organization
    . ELSO Center identification list. https://www.elso.org/Registry/SupportDocuments/CenterI-DList.aspx. Accessed October 26, 2022.
  7. ↵
    1. Stengl M,
    2. Ledvinova L,
    3. Chvojka J, et al
    . Effects of clinically relevant acute hypercapnic and metabolic acidosis on the cardiovascular system: an experimental porcine study. Crit Care 2013; 17(6):R303. doi:10.1186/cc13173
    OpenUrlCrossRefPubMed
  8. ↵
    1. Baker A,
    2. Richardson D,
    3. Craig G
    . Extracorporeal carbon dioxide removal (ECCO2R) in respiratory failure: an overview, and where next? J Intensive Care Soc 2012; 13(3):232–237. doi:10.1177/175114371201300313
    OpenUrlCrossRef
  9. ↵
    1. Arthurs GJ,
    2. Sudhakar M
    . Carbon dioxide transport. Continuing Education in Anaesthesia, Critical Care and Pain (CEACCP) 2005; 5(6):207–210. doi:10.1093/bjaceaccp/mki050
    OpenUrlCrossRef
  10. ↵
    1. Conrad SA,
    2. Broman LM,
    3. Taccone FS, et al
    . The Extracorporeal Life Support Organization Maastricht treaty for nomenclature in extra-corporeal life support. A position paper of the Extracorporeal Life Support Organization. Am J Respir Crit Care Med 2018; 198(4):447–451. doi:10.1164/rccm.201710-2130CP
    OpenUrlCrossRefPubMed
  11. ↵
    1. Bhatt N,
    2. Osborn E
    . Extracorporeal gas exchange: the expanding role of extracorporeal support in respiratory failure. Clin Chest Med 2016; 37(4):765–780. doi:10.1016/j.ccm.2016.07.015
    OpenUrlCrossRef
  12. ↵
    1. Manap HH,
    2. Abdul Wahab AK
    . Extracorporeal carbon dioxide removal (ECCO2R) in respiratory deficiency and current investigations on its improvement: a review. J Artif Organs 2017; 20(1):8–17. doi:10.1007/s10047-016-0905-x
    OpenUrlCrossRef
  13. ↵
    1. Salley SO,
    2. Song JY,
    3. Whittlesey GC,
    4. Klein MD
    . Immobilized carbonic anhydrase in a membrane lung for enhanced CO2 removal. ASAIO Trans 1990; 36(3):M486–M490. pmid:2123640
    OpenUrlPubMed
  14. ↵
    1. Cove ME,
    2. Vu LH,
    3. Ring T,
    4. Federspiel WJ,
    5. Kellum JA
    . Respiratory dialysis—a novel low bicarbonate dialysate to provide extracorporeal CO2 removal. Crit Care Med 2020; 48(7):e592–e598. doi:10.1097/CCM.0000000000004351
    OpenUrlCrossRef
  15. ↵
    1. Cressoni M,
    2. Zanella A,
    3. Epp M, et al
    . Decreasing pulmonary ventilation through bicarbonate ultrafiltration: an experimental study. Crit Care Med 2009; 37(9):2612–2618. doi:10.1097/CCM.0b013e3181a5668a
    OpenUrlCrossRefPubMed
  16. ↵
    1. Bellani G,
    2. Laffey JG,
    3. Pham T, et al
    . Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA 2016; 315(8):788–800. doi:10.1001/jama.2016.0291
    OpenUrlCrossRefPubMed
  17. ↵
    1. Bein T,
    2. Weber-Carstens S,
    3. Goldmann A, et al
    . Lower tidal volume strategy (≈3 ml/kg) combined with extracorporeal CO2 removal versus ‘conventional’ protective ventilation (6 ml/kg) in severe ARDS: the prospective randomized Xtravent-study. Intensive Care Med 2013; 39(5):847–856. doi:10.1007/s00134-012-2787-6
    OpenUrlCrossRefPubMed
  18. ↵
    1. Combes A,
    2. Tonetti T,
    3. Fanelli V, et al
    . Efficacy and safety of lower versus higher CO2 extraction devices to allow ultraprotective ventilation: secondary analysis of the SUPERNOVA study. Thorax 2019; 74(12):1179–1181. doi:10.1136/thoraxjnl-2019-213591
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Combes, A.,
    2. Fanelli, V.,
    3. Pham, T. et al
    . Feasibility and safety of extracorporeal CO2 removal to enhance protective ventilation in acute respiratory distress syndrome: the SUPERNOVA study. Intensive Care Med 2019; 45(5):592–600. doi:10.1007/s00134-019-05567-4
    OpenUrlCrossRefPubMed
  20. ↵
    1. McNamee JJ,
    2. Gillies MA,
    3. Barrett NA, et al
    . Effect of lower tidal volume ventilation facilitated by extracorporeal carbon dioxide removal vs standard care ventilation on 90-day mortality in patients with acute hypoxemic respiratory failure: the REST randomized clinical trial. JAMA 2021; 326(11):1013–1023. doi:10.1001/jama.2021.13374
    OpenUrlCrossRef
  21. ↵
    1. Goligher EC,
    2. Combes A,
    3. Brodie D, et al
    . Determinants of the effect of extracorporeal carbon dioxide removal in the SUPERNOVA trial: implications for trial design. Intensive Care Med 2019; 45(9):1219–1230. doi:10.1007/s00134-019-05708-9
    OpenUrlCrossRef
  22. ↵
    1. Grasselli G,
    2. Tonetti T,
    3. Protti A, et al
    . Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a mul-ticentre prospective observational study. Lancet Respir Med 2020; 8(12):1201–1208. doi:10.1016/S2213-2600(20)30370-2
    OpenUrlCrossRefPubMed
  23. ↵
    1. Akkanti B,
    2. Jagpal S,
    3. Darwish R, et al
    . Physiologic improvement in respiratory acidosis using extracorporeal CO2 removal with hemolung respiratory assist system in the management of severe respiratory failure from Coronavirus disease 2019. Crit Care Explor 2021; 3(3):e0372. doi:10.1097/CCE.0000000000000372
    OpenUrlCrossRef
  24. ↵
    1. Barbaro RP,
    2. MacLaren G,
    3. Boonstra PS, et al
    . Extracorporeal membrane oxygenation for COVID-19: evolving outcomes from the international Extracorporeal Life Support Organization Registry. Lancet 2021; 398(10307):1230–1238. doi:10.1016/S0140-6736(21)01960-7
    OpenUrlCrossRef
  25. ↵
    1. Allescher J,
    2. Rasch S,
    3. Wiessner JR, et al
    . Extracorporeal carbon dioxide removal with the advanced organ support system in critically ill COVID-19 patients. Artif Organs 2021; 45(12):1522–1532. doi:10.1111/aor.14044
    OpenUrlCrossRef
  26. ↵
    1. Lee SD
    . COPD: heterogeneity and personalized treatment. Berlin, Germany: Springer; 2017.
  27. ↵
    1. Gadre SK,
    2. Duggal A,
    3. Mireles-Cabodevila E, et al
    . Acute respiratory failure requiring mechanical ventilation in severe chronic obstructive pulmonary disease (COPD). Medicine (Baltimore) 2018; 97(17):e0487. doi:10.1097/MD.0000000000010487
    OpenUrlCrossRefPubMed
  28. ↵
    1. Kluge S,
    2. Braune SA,
    3. Engel M, et al
    . Avoiding invasive mechanical ventilation by extracorporeal carbon dioxide removal in patients failing noninvasive ventilation. Intensive Care Med 2012; 38(10):1632–1639. doi:10.1007/s00134-012-2649-2
    OpenUrlCrossRefPubMed
  29. ↵
    1. Burki NK,
    2. Mani RK,
    3. Herth FJF, et al
    . A novel extracorporeal CO(2) removal system: results of a pilot study of hypercapnic respiratory failure in patients with COPD. Chest 2013; 143(3):678–686. doi:10.1378/chest.12-0228
    OpenUrlCrossRefPubMed
  30. ↵
    1. Del Sorbo L,
    2. Pisani L,
    3. Filippini C, et al
    . Extracorporeal CO2 removal in hypercapnic patients at risk of noninvasive ventilation failure: a matched cohort study with historical control. Crit Care Med 2015; 43(1):120–127. doi:10.1097/CCM.0000000000000607
    OpenUrlCrossRefPubMed
  31. ↵
    1. Braune S,
    2. Sieweke A,
    3. Brettner F, et al
    . The feasibility and safety of extracorporeal carbon dioxide removal to avoid intubation in patients with COPD unresponsive to noninvasive ventilation for acute hypercapnic respiratory failure (ECLAIR study): multicentre case-control study. Intensive Care Med 2016; 42(9):1437–1444. doi:10.1007/s00134-016-4452-y
    OpenUrlCrossRefPubMed
  32. ↵
    1. Azzi M,
    2. Aboab J,
    3. Alviset S, et al
    . Extracorporeal CO2 removal in acute exacerbation of COPD unresponsive to non-invasive ventilation. BMJ Open Respir Res 2021; 8(1):e001089. doi:10.1136/bmjresp-2021-001089
    OpenUrlAbstract/FREE Full Text
  33. ↵
    1. Vasileiadis I,
    2. Alevrakis E,
    3. Ampelioti S,
    4. Vagionas D,
    5. Rovina N,
    6. Koutsoukou A
    . Acid-base disturbances in patients with asthma: a literature review and comments on their pathophysiology. J Clin Med 2019; 8(4):563. doi:10.3390/jcm8040563
    OpenUrlCrossRef
  34. ↵
    1. Brenner B,
    2. Corbridge T,
    3. Kazzi A
    . Intubation and mechanical ventilation of the asthmatic patient in respiratory failure. Proc Am Thorac Soc 2009; 6(4):371–379. doi:10.1513/pats.P09ST4
    OpenUrlCrossRefPubMed
  35. ↵
    1. Peters JI,
    2. Stupka JE,
    3. Singh H, et al
    . Status asthmaticus in the medical intensive care unit: a 30-year experience. Respir Med 2012; 106(3):344–348. doi:10.1016/j.rmed.2011.11.015
    OpenUrlCrossRefPubMed
  36. ↵
    1. Tiruvoipati R,
    2. Buscher H,
    3. Winearls J, et al
    . Early experience of a new extracorporeal carbon dioxide removal device for acute hypercapnic respiratory failure. Crit Care Resusc 2016; 18(4):261–269. pmid:27903208
    OpenUrlPubMed
  37. ↵
    1. Bromberger BJ,
    2. Agerstrand C,
    3. Abrams D, et al
    . Extracorporeal carbon dioxide removal in the treatment of status asthmaticus. Crit Care Med 2020; 48(12):e1226–e1231. doi:10.1097/CCM.0000000000004645
    OpenUrlCrossRef
  38. ↵
    1. Mikkelsen ME,
    2. Woo YJ,
    3. Sager JS,
    4. Fuchs BD,
    5. Christie JD
    . Outcomes using extracorporeal life support for adult respiratory failure due to status asthmaticus. ASAIO J 2009; 55(1):47–52. doi:10.1097/MAT.0b013e3181901ea5
    OpenUrlCrossRefPubMed
  39. ↵
    1. Lehr CJ,
    2. Zaas DW,
    3. Cheifetz IM,
    4. Turner DA
    . Ambulatory extracorporeal membrane oxygenation as a bridge to lung transplantation: walking while waiting. Chest 2015; 147(5):1213–1218. doi:10.1378/chest.14-2188
    OpenUrlCrossRef
  40. ↵
    1. Fischer S,
    2. Simon AR,
    3. Welte T, et al
    . Bridge to lung transplantation with the novel pumpless interventional lung assist device NovaLung. J Thorac Cardiovasc Surg 2006; 131(3):719–723. doi:10.1016/j.jtcvs.2005.10.050
    OpenUrlCrossRefPubMed
  41. ↵
    1. Nosotti M,
    2. Rosso L,
    3. Tosi D, et al
    . Extracorporeal membrane oxygenation with spontaneous breathing as a bridge to lung transplantation. Interact Cardiovasc Thorac Surg 2013; 16(1):55–59. doi:10.1093/icvts/ivs433
    OpenUrlCrossRefPubMed
  42. ↵
    1. Camporota L,
    2. Barrett N
    . Current applications for the use of extra-corporeal carbon dioxide removal in critically ill patients. Biomed Res Int 2016; 2016:9781695. doi:10.1155/2016/9781695
    OpenUrlCrossRef
  43. ↵
    1. Bermudez CA,
    2. Zaldonis D,
    3. Fan MH,
    4. Pilewski JM,
    5. Crespo MM
    . Prolonged use of the hemolung respiratory assist system as a bridge to redo lung transplantation. Ann Thorac Surg 2015; 100(6): 2330–2333. doi:10.1016/j.athoracsur.2015.02.104
    OpenUrlCrossRef
  44. ↵
    1. Benazzo A,
    2. Schwarz S,
    3. Frommlet F, et al
    . Twenty-year experience with extracorporeal life support as bridge to lung transplantation. J Thorac Cardiovasc Surg 2019; 157(6):2515–2525.e10. doi:10.1016/j.jtcvs.2019.02.048
    OpenUrlCrossRef
  45. ↵
    1. Doyle AJ,
    2. Hunt BJ
    . Current understanding of how extracorporeal membrane oxygenators activate haemostasis and other blood components. Front Med (Lausanne) 2018; 5:352. doi:10.3389/fmed.2018.00352
    OpenUrlCrossRef
PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 89 (12)
Cleveland Clinic Journal of Medicine
Vol. 89, Issue 12
1 Dec 2022
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
On the horizon: Extracorporeal carbon dioxide removal
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
On the horizon: Extracorporeal carbon dioxide removal
Justin Hanks, Steven Fox, Omar Mehkri, Laura W. Lund, Tracey Dill, Abhijit Duggal, Sudhir Krishnan
Cleveland Clinic Journal of Medicine Dec 2022, 89 (12) 712-718; DOI: 10.3949/ccjm.89a.21084

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
On the horizon: Extracorporeal carbon dioxide removal
Justin Hanks, Steven Fox, Omar Mehkri, Laura W. Lund, Tracey Dill, Abhijit Duggal, Sudhir Krishnan
Cleveland Clinic Journal of Medicine Dec 2022, 89 (12) 712-718; DOI: 10.3949/ccjm.89a.21084
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
    • ABSTRACT
    • WHY REMOVE CARBON DIOXIDE?
    • CARBON DIOXIDE PHYSIOLOGY
    • ECCO2R SYSTEMS
    • CARBON DIOXIDE REMOVAL MECHANISMS
    • ACUTE RESPIRATORY DISTRESS SYNDROME
    • ACUTE EXACERBATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
    • STATUS ASTHMATICUS
    • A BRIDGE TO LUNG TRANSPLANT
    • COMPLICATIONS
    • DISCLOSURES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Alpha-gal syndrome: Recognizing and managing a tick-bite–related meat allergy
  • Managing right ventricular failure in the setting of pulmonary embolism
  • Psychedelics, spirituality, and existential distress in patients at the end of life
Show more Review

Similar Articles

Subjects

  • Critical Care
  • Hospital Medicine

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire